文献速递造血干细胞移植与细胞治疗淋巴瘤

低剂量白细胞介素-2治疗激素难治性慢性移植物抗宿主病的器官特异性反应

Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease.
PubMed 文献 · Blood Adv · 2022-01-01

该报告汇总本中心五项1期或2期临床试验的105例成人激素难治性慢性移植物抗宿主病患者,评估低剂量白细胞介素-2治疗8或12周后的器官特异性缓解率。总缓解率分别为48.6%和53.3%,肝脏缓解率最高(66.7%),肺最低(19.2%)。从cGVHD诊断至IL-2启动时间短、移植至IL-2启动时间短及既往治疗少与总体及皮肤缓解相关。

要点

  • 低剂量IL-2治疗8或12周总缓解率分别为48.6%和53.3%,皮肤是最常受累器官(84%)。
  • 器官特异性缓解率:肝脏66.7%、胃肠道62.5%、皮肤36.4%、关节/肌肉/筋膜34.2%、肺19.2%。
  • 诊断至IL-2启动时间短、移植至IL-2启动时间短及既往治疗少与总体及皮肤缓解相关。

核心结论

  • 低剂量IL-2对激素难治性慢性GVHD具有器官特异性缓解,肝脏和胃肠道缓解率较高,肺和关节/肌肉/筋膜较低。
  • 从cGVHD诊断至IL-2启动时间短、移植至IL-2启动时间短及既往治疗少与总体缓解及皮肤缓解相关。
  • 作者提出应研究器官特异性损伤机制并开发器官特异性靶向治疗。

研究设计与样本

  • 汇总本中心五项1期或2期临床试验,纳入105例成人激素难治性慢性GVHD患者。
  • 评估低剂量IL-2治疗8或12周后的器官特异性缓解率、器官共同受累、器官特异性缓解预测因素及其与免疫反应的可能关联。

主要发现

  • 低剂量IL-2治疗8周总缓解率为48.6%,12周为53.3%,包括继续延长治疗患者的迟发缓解。
  • 皮肤是最常受累器官(84%)。
  • 器官特异性缓解率:肝脏66.7%、胃肠道62.5%、皮肤36.4%、关节/肌肉/筋膜34.2%、肺19.2%。
  • 多因素分析中,从cGVHD诊断至IL-2启动时间短、从移植至IL-2启动时间短及既往治疗少与总体缓解及皮肤缓解相关。
  • 免疫相关分析:第1周CD4Treg:CD4Tcon比值在总体缓解和皮肤缓解患者中显著更高;皮肤缓解与较低的总CD3 T细胞、CD4Tcon细胞和CD8 T细胞数量及较高的B细胞数量显著相关;肺缓解者所有T细胞亚群中终末效应记忆细胞计数低于无缓解者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite new therapeutic options, treatment of steroid-refractory chronic graft-versus-host disease (SR-cGVHD) remains challenging as organ involvement and clinical manifestations are highly variable. In previous trials of low-dose interleukin-2 (LD IL-2), we established the safety and efficacy of LD IL-2 for the treatment of SR-cGVHD. In the present report, we combined five phase 1 or 2 clinical trials conducted at our center to investigate organ-specific response rate, coinvolvement of organs, predictors of organ-specific response, and its possible association with immune response. For the 105 adult patients included in this report, the overall response rate after 8 or 12 weeks of LD IL-2 was 48.6% and 53.3%, including late responses in patients who continued treatment for extended periods. Skin was the most frequent organ involved (84%). The organ-specific response rate was highest in liver (66.7%) followed by the gastrointestinal tract (62.5%), skin (36.4%), joint/muscle/fascia (34.2%), and lung (19.2%). In multivariable analysis, shorter time from diagnosis of cGVHD to IL-2 initiation, shorter time from transplant to IL-2 initiation, and fewer prior therapies were associated with overall response as well as skin response. For immunologic correlates, the ratio of regulatory T cells:conventional T cells (ie, CD4Treg:CD4Tcon) ratio at 1 week was significantly higher in patients with overall and skin response; skin response was significantly associated with lower number of total CD3 T cells, CD4Tcon cells, and CD8 T cells and a higher number of B cells. For lung responders, terminal effector memory cell counts were lower within all T-cell populations compared with nonresponders. Organ-specific mechanisms of injury should be investigated, and organ-specific targeted therapies need to be developed.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kim HT, Koreth J, Whangbo J, et al. Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease. Blood Adv. 2022. PMID: 35617682. doi:10.1182/bloodadvances.2022007773

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。